New drug combo tested for tough cancers

NCT ID NCT05277051

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will shrink tumors or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remzistotug (alone or with dostarlimab, belrestotug, nelistotug, or GSK5764227)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early (Phase 1) trial focused on safety and dosing, not on proving the drug works. It is small (152 people) and may not lead to an approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm clear cell renal carcinoma colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm fallopian tube cancer gastric cancer gastric neoplasm head and neck squamous cell carcinoma neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian carcinoma primary peritoneal carcinoma renal cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site

San Francisco, California, 94158, United States
GSK Investigational Site

Charlotte, North Carolina, 28204, United States
GSK Investigational Site

Oklahoma City, Oklahoma, 73104, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19111, United States
GSK Investigational Site

Dallas, Texas, 75230, United States
GSK Investigational Site

San Antonio, Texas, 78229, United States
GSK Investigational Site

Salt Lake City, Utah, 84112, United States
GSK Investigational Site

Nedlands, Western Australia, 6009, Australia
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Chengdu, 610041, China
GSK Investigational Site

Jinan, 250117, China
GSK Investigational Site

Shanghai, 200126, China
GSK Investigational Site

Wuhan, 430022, China
GSK Investigational Site

Dijon, 21000, France
GSK Investigational Site

Lille, 59000, France
GSK Investigational Site

Chiba, 277-8577, Japan
GSK Investigational Site

Tokyo, 104-0045, Japan
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28050, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

Manchester, M20 4BX, United Kingdom
GSK Investigational Site

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.